Zivo Bioscience, Inc.
ZIVO
$11.99
-$2.92-19.58%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.64% | 467.51% | 396.86% | 1,346.34% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.64% | 467.51% | 396.86% | 1,346.34% | -- |
| Cost of Revenue | 116.54% | 572.67% | 530.95% | 5,414.29% | -- |
| Gross Profit | 52.08% | 326.09% | 252.70% | 527.27% | -- |
| SG&A Expenses | 102.45% | 74.24% | 63.11% | 53.00% | -20.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.53% | 85.43% | 71.33% | 54.50% | -23.56% |
| Operating Income | -148.07% | -83.97% | -70.68% | -53.87% | 24.29% |
| Income Before Tax | -130.39% | -72.11% | -60.90% | -52.48% | 18.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.39% | -72.11% | -60.90% | -52.48% | 18.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.39% | -72.11% | -60.90% | -52.48% | 18.50% |
| EBIT | -148.07% | -83.97% | -70.68% | -53.87% | 24.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -31.25% | 5.50% | 7.68% | 4.46% | 30.89% |
| Normalized Basic EPS | -31.25% | 5.50% | 7.68% | 4.46% | 30.89% |
| EPS Diluted | -31.25% | 5.50% | 7.68% | 4.46% | 30.89% |
| Normalized Diluted EPS | -31.25% | 5.50% | 7.68% | 4.46% | 30.89% |
| Average Basic Shares Outstanding | 71.22% | 86.16% | 71.40% | 49.27% | 27.10% |
| Average Diluted Shares Outstanding | 71.22% | 86.16% | 71.40% | 49.27% | 27.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |